Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1988 1
1993 1
1994 1
1995 1
1996 1
1999 1
2001 2
2004 1
2009 1
2010 1
2014 1
2015 1
2016 2
2017 1
2019 1
2020 2
2021 2
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.
Kurokawa K, Mitsuishi Y, Shimada N, Kawakami Y, Miura K, Miyawaki T, Asao T, Ko R, Shukuya T, Shibayama R, Nojiri S, Takahashi K. Kurokawa K, et al. Among authors: shibayama r. BMC Cancer. 2022 Oct 6;22(1):1047. doi: 10.1186/s12885-022-10133-1. BMC Cancer. 2022. PMID: 36203123 Free PMC article.
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?
Shimamura SS, Shukuya T, Asao T, Hayakawa D, Kurokawa K, Xu S, Miura K, Mitsuishi Y, Tajima K, Shibayama R, Shimada N, Takahashi F, Takahashi K. Shimamura SS, et al. Among authors: shibayama r. BMC Cancer. 2022 Mar 25;22(1):323. doi: 10.1186/s12885-022-09421-7. BMC Cancer. 2022. PMID: 35337281 Free PMC article.
Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Miyashita Y, et al. Among authors: shibayama r. Thorac Cancer. 2021 Feb;12(3):329-338. doi: 10.1111/1759-7714.13742. Epub 2020 Nov 21. Thorac Cancer. 2021. PMID: 33219754 Free PMC article.
High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
Sumiyoshi I, Okabe T, Togo S, Takagi H, Motomura H, Ochi Y, Shimada N, Haraguchi M, Shibayama R, Fujimoto Y, Watanabe J, Iwai M, Kadoya K, Iwakami SI, Takahashi K. Sumiyoshi I, et al. Among authors: shibayama r. J Transl Med. 2021 Feb 28;19(1):92. doi: 10.1186/s12967-021-02761-1. J Transl Med. 2021. PMID: 33639962 Free PMC article.
Studies on metabolic pathways of cyanate in rats.
Koshiishi I, Shibayama R, Morimoto Y, Imanari T. Koshiishi I, et al. Among authors: shibayama r. J Pharmacobiodyn. 1988 Nov;11(11):730-5. doi: 10.1248/bpb1978.11.730. J Pharmacobiodyn. 1988. PMID: 3236205
25 results